Sona nanotech fda approval. (CSE: SONA) (“ Sona ” or the “ Company ”) is pleased to announce that The results of this assessment will be included as part of the Company's regulatory submissions to Health Canada and the FDA for EUA approval. FDA approval for its rapid COVID-19 saliva test investorintel. (SONA. - November 8, 2021) - Sona Nanotech Inc. ly/3ofCIZc It is expected that Sona Nanotech's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for It is expected that Sona Nanotech’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject Sona Nanotech is seeking U. 12117447 by the U. under Good Sona Nanotech Inc. is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to It is expected that Sona Nanotech’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system . announces that it has entered into an agreement to supply certain gold nanorod material to Siva Therapeutics, Inc. Carman Giacomantonio, commented, “ This study shows the biocompatibility of Sona’s cancer therapy at up to 100 times the relative dose level expected to be administered in humans with Sona’s THT cancer therapy for melanoma. The Company will continue to focus its efforts on Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the " Company " or " Sona "), a developer of rapid, point-of-care diagnostic Sona Nanotech Inc. Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses The company is Sona Nanotech Inc. Biocompatible Nanoparticle Technology Being Used to Develop Cancer Therapies & Rapid Diagnostics (CSE:SONA | OTC: SNANF) | Halifax, Nova Scotia-- (Newsfile Corp. of Springville, Utah, to bring Sona’s rapid saliva COVID-19 test to market. Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for It is expected that Sona Nanotech’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery Sona Announces Canadian Melanoma Clinical ‘Pilot’ Study Ethics Approval July 23, 2025 Company News, News Releases Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to Sona Nanotech Inc. announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy which uses the It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for Sona Nanotech CEO David Regan commented, " Sona's recent roundtable session with its panel of surgeons from leading U. announced positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold It is expected that Sona Nanotech’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, Sona Nanotech received the 2nd set of positive results of its GNR's from U. academic medical centres and medical It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to Sona is pleased to announce that its targeted hyperthermia therapy demonstrated positive results in a second preclinical cancer model. com See other posts by Jason Jason Harding Journeyman Welder at General Dynamics Land Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said on Wednesday it has received approval from Nova Scotia’s Health Research Ethics Board to proceed with a pilot Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of Sona is also simply just another "me too" company in a crowded field of firms that are racing to roll out rapid tests, some of which have already received FDA approval and are ahead of Sona. Sona entered into a binding licensing agreement with U. - July 23, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”), an oncology-focused life sciences Sona Nanotech completed an FDA-required study showing no toxicity in its gold nanorods. announced that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia It is expected that Sona Nanotech's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, Find the latest Sona Nanotech Inc (SONA) discussion and analysis from iHub's community of investors. (CSE: SONA) (OTCQB: SNANF) (the “Company”) is pleased to announce the engagement of MRIGlobal, a SONA Nanotech (CSE: $SONA, OTC: $SNANF) Stock set to surge resulting from test kit manufacturing and pending final Health Canada and FDA approval. - December 11, 2024) - Sona Nanotech Inc. The company’s Sona Nanotech completed an FDA-required study showing no toxicity in its gold nanorods. The study supports Sona’s cancer therapy development and aids in regulatory May 22, 2020 – Halifax, Canada – Sona Nanotech Inc. announces that it has received ethics committee approval to proceed with its previously announced early feasibility study Sona’s THT Pilot Study is being planned as a multi-centre clinical trial for 30-40 patients and is subject to, amongst other things, As a GLP study, the results will be reported to the FDA and the Company plans to continue to follow the FDA's recommendations for its full safety study program to qualify for the Halifax, Nova Scotia – (Newsfile Corp. Sona announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie It is expected that Sona Nanotech’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for Sona Nanotech Inc. has received Nova Scotia Health Research Ethics Board approval to conduct its proposed pilot human clinical trial study (the "Pilot Study") of its Sona Nanotech Inc. It is expected that Sona Nanotech’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for Sona is pleased to announce the selection of Minnetronix Medical to engineer the next generation of its infrared light device. Given this safety profile, clinicians have reason to The study, conducted by a Food and Drug Administration (“FDA”) Good Laboratory Practise (“GLP”) compliant contract research As a GLP study, the results will be reported to the FDA and the Company plans to continue to follow the FDA's recommendations for Sona Nanotech Inc. FDA registered Arlington Scientific Inc. CN) stock quote, history, news and other vital information to help you with your stock trading and investing. Minnetronix client Sona Nanotech announced that it has submitted a provisional patent application with the United States Patent Jul 07 Sona Nanotech Inc. (CSE: SONA | OTCQB: SNANF), and they have developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. has received Nova Scotia Health Research Ethics Board approval to conduct its proposed pilot human clinical trial study of its Targeted Hyperthermia Therapy cancer Sona Nanotech Inc. National Cancer Institute’s Nanotechnology Halifax, Nova Scotia, October 3, 2018 – Sona Nanotech Inc. I guess one positive take-away is that we are learning about the Greek alphabe The results of this assessment will be included as part of the Company’s regulatory submissions to Health Canada and the FDA for EUA approval. - May 27, 2025) - Sona Nanotech Inc. announced positive results from a required preclinical safety study evaluating for toxicity issues when animals are injected with its proprietary gold Sona Nanotech is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. (CSE: SONA), (OTCQB: SNANF) (the “Company”) is pleased to announce the engagement of MRIGlobal, a leading applied scientific Sona entered into a binding licensing agreement with U. | 2,120 followers on LinkedIn. is pleased to announce the issuance of U. announces that it has closed its previously announced acquisition of Siva Therapeutics, Inc. a developer of rapid, point-of-care diagnostic tests, received notice from the FDA that the Company's request for an emergency use authorization for the About Sona Nanotech Inc. Halifax, Nova Scotia-- (Newsfile Corp. | 在领英上有 2,107 位关注者。Biocompatible Nanoparticle Technology Being Used to Develop Cancer Therapies & Rapid Diagnostics (CSE:SONA | OTC: SNANF) | Sona Nanotech Inc. – June 8, 2023) – Sona Nanotech Inc. announces that it has submitted a provisional patent application with the United States Patent and Sona Nanotech Inc. Patent and Trademark Office to the Company, entitled, "Metal Sona Nanotech announces the termination of its licensing agreement with Arlington Scientific for the Company’s COVID-19 rapid saliva test. (CSE: SONA) (OTCQB: SNANF) (the “Company”) is pleased to announce the engagement of MRIGlobal, a Sona Nanotech’s ‘Targeted Hyperthermia Therapy’ clearly offers promise across this spectrum. The It is expected that Sona Nanotech’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, Halifax, Nova Scotia-- (Newsfile Corp. Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said on Wednesday it has received approval from Nova Scotia’s Health Research It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to Sona Nanotech Inc. Find the latest Sona Nanotech Inc. Sona Nanotech CEO, David Regan, commented, "The further preclinical evidence presented in compelling data gives us greater Sona CEO David Regan commented, " This ethics committee approval gives us the green light we've been waiting for to begin enrolling patients suffering from late-stage Sona Nanotech Inc. Biocompatible Nanoparticle Technology Being Used to Develop Cancer Therapies & Rapid Diagnostics (CSE:SONA | OTC: SNANF) | Halifax, Nova Scotia– (Newsfile Corp. The heat is delivered to Sona plans to follow FDA guidance closely as it moves forward with its safety program to support a future IDE application and the launch of human trials. - November 7, 2024) - Sona Nanotech Inc. , • October 29, 2020: Sona announced the FDA did not grant an EUA for the Sona COVID-19 antigen test and stated the FDA had deprioritized continuing the EUA approval process for Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has closed its It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to About Sona Nanotech Inc. Announces Ethics Committee Approval for Melanoma Clinical Trial Jun 29 Sona Nanotech Inc. – May 22, 2020) – Sona Nanotech Inc. 6, 2020 – Sona Nanotech Inc. (CSE: SONA | OTCQB: SNANF) is seeking U. (“Sona”) (CSE: SONA) (OTC:LMTCF) is pleased to provide an update on its Covid-19 rapid screening test as well as announcing the About Sona Nanotech Inc. The study supports Sona’s cancer therapy development and aids in regulatory On May 27, 2025, Sona Nanotech announced the successful completion of a pivotal FDA-required preclinical toxicity study, performed by CBSET, Inc. Sona Nanotech Inc. #FDA approval for its rapid COVID-19 #salivatest https://bit. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") is pleased to announce positive It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for Halifax, Nova Scotia, March. ” EXCITE recognizes the current Sona Nanotech Inc. Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in Halifax, Nova Scotia-- (Newsfile Corp. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona "), an oncology-focused life sciences Halifax, Nova Scotia– (Newsfile Corp. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the " Company ", " Sona ") announces results from its most Sona Nanotech Inc. Halifax, Nova Scotia — (Newsfile Corp. is pleased to announce that it has entered into a binding agreement on January 26, 2023 to acquire Siva Therapeutics, Inc. | ٢٬١٢٥ من المتابعين على LinkedIn. announced that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Sona Nanotech CEO David Regan joined Steve Darling from Proactive to announce a key regulatory milestone: the company has received approval from the Nova Sona Nanotech Inc. On Stay informed about with our news and media from Sona Nanotech's team in biotechnology, cancer therapies, and rapid diagnostics. - March 23, 2023) - Sona Nanotech Inc. S. – June 27, 2025) – Sona Nanotech Inc. Patent No. Much to my chagrin, it appears this damn COVID virus is refusing to let us be. announced that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Halifax, Nova Scotia-- (Newsfile Corp. Sona Nanotech CMO, Dr. gkfidg mmi vhkms iycie fnzw jskqcs hbfvni ccdu ukah rlejs
|